Saturday 17 October 2026
Export KALA’s income statement to Excel — free account
KALA BIO, Inc.
KALA Healthcare Biotechnology
KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.
0.19
0.00
0.00%
Follow KALA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (345.32%) | (238.69%) | (279.20%) | 3,969.10% |
+8 more TTM periods Free account |
|
| (43.23%) | (64.90%) | (83.05%) | (90.62%) | ||
ROIC |
(722.69%) | (948.11%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(111.46%) | (182.64%) | (385.65%) | 465.65% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(267.70) | (2.19) | (196.88) | (228.86) | |
Free Cash Flow |
(19.86) | (26.06) | (32.09) | (32.22) | |
Capital Expenditures |
— | — | (0.10) | (0.19) | |
| Other line items | |||||
Cash ROIC |
(122.06%) | (133.48%) | (220.51%) | (78.90%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | (11.95) | (8.48) | |
Operating CF/Net income |
1.97 | 1.33 | 1.19 | 0.89 | |
Depreciation/Fixed assets |
— | — | 0.00 | 1.83 | |
Capex/Depreciation |
— | — | 0.29 | (0.17) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(267.70) | (2.19) | (196.26) | (227.51) | |
Capex per Share |
0.00 | 0.00 | (0.61) | (1.35) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates